Phase I trial of tirapazamine and cyclophosphamide in children with refractory solid tumors: A pediatric oncology group study

Journal of Clinical Oncology

Volumn 22, Issue 8, 2004, Pages 1413-1419

  Aquino, Victor M ^a   Weittnan, Steve D ^a   Winick, Naomi J ^a   Blaney, Susan ^a   Furman, Wayne L ^a   Kepner, James L ^a   Bonate, Peter ^a   Krailo, Mark ^a   Qu, Wenchun ^a   Bernstein, Mark ^a  

^a UNIVERSITY OF TEXAS SOUTHWESTERN MEDICAL CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLOPHOSPHAMIDE; TIRAPAZAMINE; ANTINEOPLASTIC AGENT; TRIAZINE DERIVATIVE;

AREA UNDER THE CURVE; ARTICLE; BONE MARROW; CLINICAL ARTICLE; CLINICAL TRIAL; DOSE RESPONSE; FEMALE; HUMAN; MALE; NEUROBLASTOMA; NEUTROPENIA; OTOTOXICITY; PHASE 1 CLINICAL TRIAL; PRIORITY JOURNAL; RHABDOMYOSARCOMA; SOLID TUMOR; ADOLESCENT; ADULT; CHEMICALLY INDUCED DISORDER; CHILD; METABOLISM; NEOPLASM; PRESCHOOL CHILD; TUMOR RECURRENCE;

ADOLESCENT; ADULT; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; CHILD; CHILD, PRESCHOOL; CYCLOPHOSPHAMIDE; FEMALE; HUMANS; MALE; NEOPLASM RECURRENCE, LOCAL; NEOPLASMS; NEUTROPENIA; TRIAZINES;

EID: 2342618217     PISSN: 0732183X     EISSN: None     Source Type: Journal    
DOI: 10.1200/JCO.2004.07.111     Document Type: Article

References (41)

1. Brown JM, Giaccia AJ: Tumour hypoxia: The picture has changed in the 1990s. Int J Radiat Biol 65:95-102, 1994
2. Rockwell S: Use of hypoxia-directed drugs in the therapy of solid tumors. Semin Oncol 19:29-40, 1992 (4 suppl 11)
3. Wouters BG, Wang LH, Brown JM: Tirapazamine: A new drug producing tumor specific enhancement of platinum-based chemotherapy in non-small-cell lung cancer. Ann Oncol 10:29-S33, 1999 (suppl 5)
4. Aboagye EO, Dillehay LE, Bhujwalla ZM, et al: Hypoxic cell cytotoxin tirapazamine induces acute changes in tumor energy metabolism and pH: A 31P magnetic resonance spectroscopy study. Radiat Oncol Investig 6:249-254, 1998
5. Investigator's Brochure: Tirapazamine. Sanofi-Sterling-Wintrop, 1995
6. Kelson AB, McNamara JP, PandeyA, et al: 1,2,4-Benzotriazine 1,4-dioxides: An important class of hypoxic cytotoxins with antitumor activity. Anticancer Drug Des 13:575-592, 1998
7. Minchinton AI, Brown JM: Improving the effectiveness of the bioreductive antitumor agent SR 4233 by induced hypoxia. Adv Exp Med Biol 317:177-181, 1992
8. B. Shibata T, Shibamoto Y, Sasai K, et al: Tirapazamine: Hypoxic cytotoxicity and interaction with radiation as assessed by the micronucleus assay. Br J Cancer Suppl 27:S61-S64, 1996
9. Skarsgard LD, Vinczan A, Skwarchuk MW, et al: The effect of low pH and hypoxia on the cytotoxic effects of SR4233 and mitomycin C in vitro. Int J Radiat Oncol Biol Phys 29:363-367, 1994
10. Wilder RB, McGann JK, Sutherland WR, et al: The hypoxic cytotoxin SR 4233 increases the effectiveness of radioimmunotherapy in mice with human non-Hodgkin's lymphoma xenografts. Int J Radiat Oncol Biol Phys 28:119-126, 1994
11. Gatzemeier U, Rodriguez G, Treat J, et al: Tirapazamine-cisplatin: The synergy. Br J Cancer 77:15-17, 1998 (suppl 4)
12. Kovacs MS. Hocking DJ, Evans JW, et al: Cisplatin anti-tumour potentiation by tirapazamine results from a hypoxia-dependent cellular sensitization to cisplatin. Br J Cancer 80: 1245-1251, 1999
13. von Pawel J, von Roemeling R, Gatzemeier U, et al: Tirapazamine plus cisplatin versus cisplatin in advanced non-small-cell lung cancer: A report of the international CATAPULT I study group. Cisplatin and tirapazamine in subjects with advanced previously untreated non-small-cell lung tumors. J Clin Oncol 18:1351-1359, 2000
14. Dorie MJ, Brown JM: Modification of the antitumor activity of chemotherapeutic drugs by the hypoxic cytotoxic agent tirapazamine. Cancer Chemother Pharmacol 39:361-366, 1997
15. Langmuir VK, Rooker JA, Osen M, et al: Synergistic interaction between tirapazamine and cyclophosphamide in human breast cancer xenografts. Cancer Res 54:2845-2847, 1994
16. Herman TS, Teicher BA, Coleman CN: Interaction of SR-4233 with hyperthermia and radiation in the FSaIIC murine fibrosarcoma tumor system in vitro and in vivo. Cancer Res 50:5055-5059, 1990
17. Shulman LN, Buswell L, Riese N, et al: Phase I trial of the hypoxic cell cytotoxin tirapazamine with concurrent radiation therapy in the treatment of refractory solid tumors. Int J Radiat Oncol Biol Phys 44:349-353, 1999
18. Zeman EM, Lemmon MJ, Brown JM: Aerobic radiosensitization by SR 4233 in vitro and in vivo. Int J Radiat Oncol Biol Phys 18:125-132, 1990
19. Zhang M, Stevens G: Effect of radiation and tirapazamine (SR-4233) on three melanoma cell lines. Melanoma Res 8:510-515, 1998
20. Senan S, Rampling R, Graham MA, et al: Phase I and pharmacokinetic study of tirapazamine (SR 4233) administered every three weeks. Clin Cancer Res 3:31-38, 1997
21. Johnson CA, Kilpatrick D, von Roemeling R, et al: Phase I trial of tirapazamine in combination with cisplatin in a single dose every 3 weeks in patients with solid tumors. J Clin Oncol 15: 773-780, 1997
22. Aghajanian C, Brown C, O'flaherty C, et al: Phase I study of tirapazamine and cisplatin in patients with recurrent cervical cancer. Gynecol Oncol 67:127-130, 1997
23. Bedikian AY, Legha SS, Eton O, et al: Phase II trial of tirapazamine combined with cisplatin in chemotherapy of advanced malignant melanoma. Ann Oncol 8:363-367, 1997
24. Bedikian AY, Legha SS, Eton O, et al: Phase II trial of escalated dose of tirapazamine combined with cisplatin in advanced malignant melanoma. Anticancer Drugs 10:735-739, 1999
25. Del Rowe J, Scott C, Werner-Wasik M, et al: Single-arm, open-label phase II study of intravenously administered tirapazamine and radiation therapy for glioblastoma multiforme. J Clin Oncol 18:1254-1259, 2000
26. Dorie MJ, Brown JM: Tumor-specific, schedule-dependent interaction between tirapazamine (SR 4233) and cisplatin. Cancer Res 53:4633-4636, 1993
27. Holden SA, Teicher BA, Ara G, et al: Enhancement of alkylating agent activity by SR4233 in the FSaIIc murine fibrosarcoma. J Natl Cancer Inst 84:187-193, 1992
28. Jones GD, Weinfeld M: Dual action of tirapazamine in the induction of DNA strand breaks. Cancer Res 56:1584-1590, 1996
29. Lartigau E, Guichard M: The effect of tirapazamine (SR-4233) alone or combined with chemotherapeutic agents on xenografted human tumours. Br J Cancer 73:1480-1485, 1996
30. Lee DJ, Trotti A, Spencer S, et al: Concurrent tirapazamine and radiotherapy for advanced head and neck carcinomas: A Phase II study. Int J Radiat Oncol Biol Phys 42:811-815, 1998
31. Siim BG, van Zijl PL, Brown JM: Tirapazamine-induced DNA damage measured using the comet assay correlates with cytotoxicity towards hypoxic tumour cells in vitro. Br J Cancer 73:952-960, 1996
32. Siim BG, Menke DR, Dorie MJ, et al: Tirapazamine-induced cytotoxicity and DNA damage in transplanted tumors: Relationship to tumor hypoxia. Cancer Res 57:2922-2928, 1997
33. Pazdur R, Diaz-Canton E, Reddy S, et al: Phase I study of intravenously administered tirapazamine (WIN 59075) plus cyclophosphamide. Ann Oncol 7:98, 1996 (suppl 1)
34. National Cancer Institute: Guidelines for Reporting of Adverse Drug Reactions. Division of Cancer Treatment, National Cancer Institute, Bethesda, MD, 1988
35. Cawello W, Antonucci T: The correlation between pharmacodynamics and pharmacokinetics: Basics of pharmacokinetics-pharmacodynamics modeling. J Clin Pharmacol 37:65S-69S, 1997 (suppl 1)
36. Brown JM, Giaccia AJ: The unique physiology of solid tumors: Opportunities (and problems) for cancer therapy. Cancer Res 58:1408-1416, 1998
37. Brown JM: SR 4233 (tirapazamine): a new anticancer drug exploiting hypoxia in solid tumours. Br J Cancer 67:1163-1170, 1993
38. Wang J, Biedermann KA, Brown JM: Repair of DNA and chromosome breaks in cells exposed to SR 4233 under hypoxia or to ionizing radiation. Cancer Res 52:4473-1477, 1992
39. Lloyd RV, Duling DR, Rumyantseva GV, et al: Micrsomal reduction of 3-amino-1,2,4-benzotriazine-1,4-dioxide to a free radical. Mol Pharmacol 40:440-445, 1991
40. Doherty N, Hancock SL, Kaye S, et al: Muscle cramping in phase I clinical trials of tirapazamine (SR 4233) with and without radiation. Int J Radiat Oncol Biol Phys 29:379-382, 1994
41. Masunaga SI, Ono K, Suzuki M, et al: Usefulness of tirapazamine as a combined agent in chemoradiation and thermo-chemoradiation therapy at mild temperatures: Reference to the effect on intratumor quiescent cells. Jpn J Cancer Res 91:566-572, 2000